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The reason certain self-antigens are consistently tar-
geted by autoantibodies may be because they are
self-adjuvants. Two papers in this issue of Immunity
provide important insights into the contribution of
Toll-like receptors in systemic autoimmune disease
(Berland et al., 2006; Christensen et al., 2006).
Toll-like receptors (TLRs) were initially described as
a family of pattern-recognition receptors (PRRs) able
to distinguish microbial molecular patterns from host
constituents and then rapidly mobilize the innate and
adaptive immune systems in response to infection.
TLR9, TLR7, TLR3, and TLR8 (in humans) make up
a TLR subfamily committed to the recognition of nucleic
acids. TLR9 is best known as the receptor for bacterial
and viral DNA where hypomethylated CpG motifs serve
as a prominent ligand. TLR7 and TLR8 preferentially
recognize ssRNA that has undergone minimal posttran-
scriptional modification, a feature more common to
microbial than eukaryotic RNA (Kariko et al., 2005). In
contrast to other TLRs, such as TLR4 (the lipopolysac-
charide receptor receptor), members of this subfamily
are sequestered inside the cell, where they most likely
access their ligands in endosomal or lysosomal com-
partments. Under normal conditions, this location pre-
sumably precludes interaction with host nucleic acid
components. Nevertheless, recent in vitro experiments
have implicated TLR9 and TLR7 in the activation of both
autoreactive B cells and dendritic cells by DNA- and
RNA-associated self-antigens, respectively.
According to the current paradigm, autoreactive B
cells bind self-DNA or RNA through their B cell receptor
(BCR), either directly or through an associated protein.
This leads to the uptake of autoantigen, delivery to
a TLR7- or TLR9-containing compartment, and in cer-
tain cases, the subsequent detection of the autoantigen
by TLR9 or TLR7. In this sense, self-molecules such as
nucleic acids that can be recognized by TLRs are au-
toadjuvants. A combination of signaling events, initiated
by both the BCR and the TLR, then leads to B cell acti-
vation and autoantibody production. This kind of B cell
response may be enhanced by a combination of genetic
or environmental factors. For example, interferon-a
(IFN-a), produced by plasmacytoid dendritic cells
(pDCS) as well as other cell types in response to viral in-
fection, markedly increases B cell expression of TLR7.
These autoantibodies can then bind to autoantigen
and form autoantigen-containing immune complexes
(IC) that can be detected, internalized, and delivered
to a TLR-containing compartment by Fcg receptors
(FcgR) expressed on antigen-presenting cells such as
pDCs. This in turn stimulates additional production of
IFN-a and other cytokines that further promote autoan-
tibody production and additional proinflammatory re-
sponses. This model is supported by a number of in vitrostudies involving TLR7 and TLR9 inhibitors, transfected
cell lines, and TLR9- or TLR7-deficient murine B cells
and DCs and has clearcut therapeutic implications: tar-
geting TLR9 or TLR7 ligand interactions, or their ensu-
ing signaling cascades, for the treatment of systemic
autoimmune disease. How these studies relate to auto-
immune disease in vivo has been much less clear. More-
over, TLR-independent pathways for DNA- or RNA-
dependent DC activation have also been identified;
therefore, the actual role for TLR9 and TLR7 in the de-
velopment of systemic autoimmune disease has been
questioned (Ishii and Akira, 2005).
To test the in vivo relevance of TLR9 expression on
the development of systemic autoimmunity, Christen-
sen et al. initially compared Tlr92/2 and Tlr9+/+ autoim-
mune prone Fas-deficient (lpr/lpr) mice on a mixed ge-
netic background. The outcome was more complex
than anticipated. The first question was whether TLR9
deficiency would have an impact on autoantibody pro-
duction. The criteria used by this group, homogeneous
nuclear staining of HEp2 cells, is considered a definitive
assay for the detection of dsDNA-reactive antibodies.
The extent of homogenous staining was severely de-
creased, although the mice continued to make anti-
bodies against RNA-associated antigens, as evidenced
by cytoplasmic and speckled nuclear HEp2 staining
patterns. The absence of dsDNA antibodies was con-
firmed by the inability of the TLR9-deficient sera to bind
the kinetoplast of Crithidia lucidia (a gigantic mitochon-
drion located at the base of the flagellum). However sev-
eral other groups, using mainly ELISA-based DNA as-
says to study additional sources of lpr/lpr mice or the
Ali5 model of SLE, concluded that TLR9 deficiency
had little if any effect on DNA titers, even though one
group reported a significant decrease in anti-nucleo-
some binding activity (Lartigue et al., 2006; Wu and
Peng, 2006; Yu et al., 2006). The issue has been further
addressed in the current Christenson report, where the
authors have now carefully compared a large panel of
MRL/lpr Tlr92/2 and Tlr9+/+ mice. Again the Tlr92/2mice
have a dramatic decrease in dsDNA-reactive autoanti-
bodies as measured by HEp2 and Crithidia staining
patterns. A side-by-side comparison shows that these
staining patterns do not correlate with DNA titers as de-
termined by a standard DNA ELISA. Overall, the data
demonstrate that TLR9 does lead to a reduction in
dsDNA titers and suggest that it may be important to
re-evaluate the criteria (ELISA assays) used to catego-
rize patient sera in various clinical studies.
In this regard, it is interesting to note that the 564 au-
toreactive BCR, used in the Berland study, was derived
from a hybridoma cell line that binds to ssDNA (and poly
I) by ELISA but gives a mainly cytoplasmic and nucleolar
staining pattern when tested in a HEp2 staining assay.
As discussed below, B cells expressing the 564 recep-
tor appear to be activated by TLR7 and, by extension,
through an RNA-associated autoantigen. RNA-associ-
ated autoantigens and TLR7 gained further prominence
this past summer when the genetic basis of the Yaa
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398Figure 1. Discrepant Outcomes of TLR9 and
TLR7 Deficiency in Autoimmune-Prone lpr/
lpr Mice
Cellular debris released from dying or dam-
aged cells can be recognized by autoreactive
BCRs and then transported by the BCR to an
internal endosomal or lysosomal compart-
ment, where TLR9 can be effectively engaged
by DNA (left) and TLR7 can be effectively en-
gaged by RNA (right). IFNa enhances the re-
sponse to RNA or RNA-associated autoanti-
gens by upregulating TLR7 expression.
Cells activated by both the BCR and either
TLR9 or TLR7 secrete autoantibodies that
can then bind to the autoantigen and form im-
mune complexes that then bind to an FcgR
expressed by plasmacytoid DCs (and other
antigen-presenting cells) and are then trans-
ported to an internal endosomal or lysosomal
compartment, where TLR9 and TLR7 can be
effectively engaged. The activated pDCs up-
regulate costimulatory molecules and pro-
duce cytokines that promote further auto-
antibody secretion and also drive other
proinflammatory aspects of the immune re-
sponse. For reasons yet to be determined,
TLR9-deficient mice develop more severe
clinical disease than the TLR-sufficient con-
trol group, whereas TLR7-deficient mice de-
velop less severe disease.mutation (Y chromosome autoimmune accelerator) was
revealed as a duplication and Y chromosome transloca-
tion of a 4 Mb X chromosome segment that happens to
include the gene for TLR7 (Pisitkun et al., 2006; Subra-
manian et al., 2006). Yaa mice express twice the normal
amount of TLR7 and respond twice as well as normal B
cells to synthetic TLR7 ligands. Importantly, the Yaa
mutation severely exacerbates the clinical SLE-like dis-
ease of B6.Sle1 mice and B6 FcgRIIb-deficient mice and
skews the autoantibody repertoire of these mice toward
reactivity with RNA-associated autoantigens.
Despite the controversy over DNA reactivity, there is
a general consensus that TLR9-deficient autoimmune-
prone mice have exacerbated clinical disease, including
more severe glomerulonephritis, a significantly short-
ened lifespan, and in some models, elevated titers of
autoantibodies reactive with RNA-associated autoanti-
gens. The disease severity and RNA-skewed autoanti-
body repertoire is reminiscent of the phenotype of Yaa
autoimmune-prone mice. Remarkably, Tlr72/2 lpr/lpr
mice, described for the first time in the current Christen-
son report, develop a phenotype quite distinct from
their Tlr92/2 counterparts. These mice fail to make auto-
antibodies reactive with common RNA autoantigens, al-
though they still produce antibodies against dsDNA.
Most importantly, they have less severe disease than
their TLR7-sufficient littermates, as evidenced by fewer
activated lymphocytes and pDCs and a modest de-
crease in renal disease (Figure 1). The contribution of
TLR7 to autoantibody production is further illustrated
in the Berland paper. The 564 receptor was initiallyselected for gene-targeting studies based on a shared
idiotype with antibodies eluted from the kidneys of
SWRxNZB mice and the pathogenicity of 564 mAb on
transfer to young SWRxNZB mice. Even though most
of the B cells in the 564 knock-in model appear to be
anergic, some 564-expressing B cells must become ac-
tivated in light of the fact that the mice spontaneously
produce 564 IgG antibodies, even when the targeted re-
ceptor is bred onto a Rag22/2 background. Remark-
ably, in TLR7-deficient 564 mice, the spontaneous pro-
duction of 564 IgG disappears. Together, these papers
point to a definitive in vivo role for TLR7 in the produc-
tion of autoantibodies reactive to RNA-associated auto-
antigens as well as in other aspects of clinical disease.
However, it will be important follow up these initial data
with long-term survival studies.
Exactly why the Tlr92/2 and Tlr72/2 mice develop
such discrepant phenotypes is quite mysterious. Possi-
ble explanations include a role for TLR9 (and not TLR7?)
in the clearance of apoptotic debris—perhaps TLR9
contributes to the production of antibodies that facilitate
the scavenger-cell activity. Alternatively, ICs containing
RNA autoantigens may simply be more pathogenic than
DNA-containing (TLR9-dependent) ICs, and in the ab-
sence of anti-dsDNA-producing cells, there is more
room in the plasmablast and plasma cell niche for the
RNA-reactive clones to expand. It is also theoretically
possible that TLR9 is preferentially expressed by a criti-
cal regulatory cell that normally limits self-recognition.
Remarkably little is currently known about differential
expression of TLR9 and TLR7 or unique functional
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What data are available usually come from studies that
utilize artificial ligands such as CpG oligonucleotides
(for TLR9) or R848 (for TLR7) and may not accurately
reflect the activity of more physiologically relevant
ligands.
These reports leave unanswered a number of critical
questions, including the outcome of combined TLR9,
TLR7 deficiency. In early studies on a mixed back-
ground, mice lacking the TLR adaptor protein, MyD88,
did not produce dsDNA- or Sm-reactive antibodies, sug-
gesting that the combined deficiency would severely de-
crease total autoantibody production, but a contribution
for interleukin-1 family members could not be ruled out
in these studies. It will also be important to extend the
analysis to animal models other than lpr that may be
more or less dependent on either TLR9 or TLR7.
B6.FcgRIIb2/2 mice that inherit the anti-DNA 56R heavy
chain produce high titers of pathogenic DNA autoanti-
bodies at an early age, and IgG forms of those antibodies
are not produced by TLR9-deficient B6.FcgRIIb2/2 56R
knockin mice (Ehlers et al., 2006). Moreover, the Yaa mu-
tation differentially affects BCR transgenic lines that ex-
press DNA and red-blood-cell-reactive receptors (Moll
et al., 2005). Finally, what about non-nucleic-acid-asso-
ciated autoantibodies—are they autoadjuvants? Per-
haps the TLR9 or TLR7 link to DNA- or RNA-associated
autoantigens is just the tip of the iceberg. Additional
PRRs may well contribute to other types of autoanti-
bodies; possibilities include TLR4 and phospholipids
or even non-TLR PRRs reactive with cell-damage- or
death-associated epitopes. Only time will toll!Immunity 25, September 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.20
Transforming Growth Factor-b:
Taking Control of T Cells’
Life and Death
To determine how transforming growth factor-b (TGF-
b) controls T cell function, Marie et al. (2006) and Li
et al. (2006a) created mice with T cells lacking TGF-b
signaling receptors. Both report that TGF-b signaling
by T cells is absolutely essential for tolerance and
homeostasis.
Each day, millions of T cells are stimulated to eliminate
harmful microbial invaders without causing secondary
tissue injury or triggering aggressive self-reactive T cells.
Cell-intrinsic and cell-extrinsic regulatory mechanisms
maintain immunologic tolerance and keep the total num-
ber of T cells in homeostatic balance. The hematopoietic
cell-derived cytokine, TGF-b1 has a well-established
role in maintaining this balance. This cytokine controls
T cell activation, proliferation, differentiation, and sur-
vival. Evidence exists that TGF-b1 also plays a role inAnn Marshak-Rothstein1
1Department of Microbiology
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Boston, Massachusetts 02215
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the generation, function, and survival of CD4+ regulatory
T (Treg) cells. Therefore, whether the maintenance of
tolerance and homeostasis is a direct effect of TGF-b
on T cells and/or of regulatory T cell control is not known.
In this issue of Immunity, Marie et al. (2006) and Li et al.
(2006a) have each addressed this question by creating
mice with T cells that lack the ability to respond to
TGF-b.
TGF-b1 is a member of a family of cytokines that are
produced by many cell types and regulate the develop-
ment, function, and expansion and/or survival of the
cells of many organ systems. It is generally secreted
as a latent, precursor molecule and converted to its
active form extracellularly. TGF-b signaling is mediated
mainly by two serine-threonine kinase receptors, TGF-
bRI and TGF-bRII, which activate Smad transcription
factors. Crosstalk between Smads and other transcrip-
tional regulators determines functional properties de-
veloped by the cell.
TGF-b has pleotropic positive and negative regulatory
effects on T cells. In general, it inhibits conventional
T cells but supports the homeostasis of both natural
and adaptive Treg subsets. It inhibits T cell proliferation
